Iluvien (Fluocinolone Acetonide)

Fluocinolone acetonide binds to glucocorticoid receptors inside ocular cells, modifying gene transcription. This reduces production of inflammatory cytokines, lowers vascular permeability, and limits leukocyte infiltration, which together decrease fluid accumulation and inflammation in the retina and posterior segment.

The dosing regimen for Iluvien is determined by the prescribing ophthalmologist. The product is a 0.19 mg sustained‑release implant that is inserted once by intravitreal injection; the clinician decides the timing of any repeat implantation based on the patient’s response.

Safety data for Iluvien in pregnancy or lactation are limited, and the product is not classified in a specific pregnancy category. Clinicians should weigh potential benefits against unknown risks and consider alternative therapies when treating pregnant or nursing patients.

To request Iluvien, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed), and import documentation.

Iluvien offers a sustained‑release corticosteroid option that can last up to 36 months, reducing the need for frequent injections. Compared with anti‑VEGF agents, it may be chosen for patients who are non‑responsive to anti‑VEGF therapy or who prefer fewer clinic visits, but it carries a higher risk of intraocular pressure rise and cataract formation.

Iluvien should be stored at 2‑8 °C in a refrigerator. Keep the implant in its original packaging, protect it from light, and avoid freezing or shaking the product. Do not store at ambient temperature.

Iluvien is delivered by a single intravitreal injection performed by a qualified ophthalmic surgeon. The 0.19 mg implant is placed into the vitreous cavity, where it releases fluocinolone acetonide slowly over an extended period.

The most serious risks include endophthalmitis (a severe eye infection), retinal detachment, and persistent elevation of intraocular pressure that may require surgical intervention. Patients should be monitored closely for signs of infection, pressure changes, and retinal integrity after implantation.

Iluvien is contraindicated in patients with active ocular infections, uncontrolled glaucoma, or known hypersensitivity to fluocinolone acetonide or any component of the implant. Caution is also advised for individuals with a history of steroid‑induced intraocular pressure spikes.